Refractory Hypoglycaemia in Hepatocellular Carcinoma Treated with TACE Leading to Tumour Lysis Syndrome- A Double Trouble
Published: January 1, 2022 | DOI: https://doi.org/10.7860/JCDR/2022/52274.15923
Saurabh Kumar, Ishita B Sen, Vivek Vij, Ashish Singhal, Ajitabh Srivastava
1. Consultant Interventional Radiologist, Department of Interventional Radiology, Fortis Memorial Research Institute, Gurugram, Haryana, India.
2. Director, Department of Nuclear Medicine, Fortis Memorial Research Institute, Gurugram, Haryana, India.
3. Director, Department of Liver Transplant and Hepatobiliary Surgery, Fortis Memorial Research Institute, Gurugram, Haryana, India.
4. Senior Consultant, Department of Liver Transplant and Hepatobiliary Surgery, Fortis Memorial Research Institute, Gurugram, Haryana, India.
5. Senior Consultant, Department of Liver Transplant and Hepatobiliary Surgery, Fortis Memorial Research Institute, Gurugram, Haryana, India.
Correspondence
Dr. Saurabh Kumar,
Consultant Interventional Radiologist, Department of Interventional Radiology,
Fortis Memorial Research Institute, Sector-44, Gurugram, Haryana, India.
E-mail: sunny_mamc911@yahoo.com
Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer. Hypoglycaemia is a well-established paraneoplastic manifestation of HCC. Cytoreduction by surgery or Transarterial Chemoembolisation (TACE) has been effective treatment options in such cases when conservative treatment fails. Tumour Lysis Syndrome (TLS) is an oncological emergency following treatment of malignancies with high cell turnover and can be seen in liver-directed therapy in the form of both ablative therapies and transarterial therapies for HCC. Authors present a rare case of 65-year-old male, with HCC presented with symptoms of refractory hypoglycaemia which was managed by TACE procedure with further patient developing TLS which was medically managed.
[
FULL TEXT ] | [ PDF]